M. Abdullaev, B. Kantemirova, E. Chernysheva, A. Romanova
{"title":"COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY","authors":"M. Abdullaev, B. Kantemirova, E. Chernysheva, A. Romanova","doi":"10.29039/2712-8164-2023-1-17-26","DOIUrl":null,"url":null,"abstract":"The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).","PeriodicalId":269283,"journal":{"name":"ASTRAKHAN MEDICAL JOURNAL","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ASTRAKHAN MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29039/2712-8164-2023-1-17-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).